Figure 5.
TLR9 antagonist ODN2088 lowers SBP in SHR, and TLR9 agonist ODN2395 increases SBP in previously normotensive rats. Systolic blood pressure responses (A) across ODN2088 treatment in WKY and SHR (arrows depict when ODN2088 or Veh were administered) and (B) post-ODN2395 treatment. n = 4–9. Repeated-measures ANOVA (with Bonferroni correction): *P < 0.05 vs. SHR-Veh; one-way ANOVA: *P < 0.05 vs. Veh.